AAAAAA

   
Results: 1-7 |
Results: 7
HIGH-FREQUENCY OF P53 MUTATIONS IN NONSMALL CELL LUNG-CANCER DETECTEDWITH YEAST FUNCTIONAL ASSAY
Authors: MONZO M GUMERLOCK P SHI XB MARTIN G GOMEZCODINA J PIFARRE A ASTUDILLO J GANDARA D ROSELL R
Citation: M. Monzo et al., HIGH-FREQUENCY OF P53 MUTATIONS IN NONSMALL CELL LUNG-CANCER DETECTEDWITH YEAST FUNCTIONAL ASSAY, Annals of oncology, 9, 1998, pp. 423-423
PROPOSAL FOR CLASSIFYING THE ACUTE EMETOGENICITY OF CANCER-CHEMOTHERAPY
Authors: HESKETH PJ KRIS MG GRUNBERG SM BECK T HAINSWORTH JD HARKER G AAPRO MS GANDARA D LINDLEY CM
Citation: Pj. Hesketh et al., PROPOSAL FOR CLASSIFYING THE ACUTE EMETOGENICITY OF CANCER-CHEMOTHERAPY, Journal of clinical oncology, 15(1), 1997, pp. 103-109
4 ARM ORAL DOSE-RESPONSE TRIAL OF DOLASETRON MESYLATE (DM) FOR PREVENTION OF EMESIS INDUCED BY PLATINUM-CONTAINING MODERATELY EMETOGENIC CHEMOTHERAPY (CT)
Authors: GROTE T MODIANO M GANDARA D COCQUYT V HAHNE W
Citation: T. Grote et al., 4 ARM ORAL DOSE-RESPONSE TRIAL OF DOLASETRON MESYLATE (DM) FOR PREVENTION OF EMESIS INDUCED BY PLATINUM-CONTAINING MODERATELY EMETOGENIC CHEMOTHERAPY (CT), European journal of cancer, 31A, 1995, pp. 1219-1219
COMPARATIVE CLINICAL-TRIAL OF GRANISETRON AND ONDANSETRON IN THE PROPHYLAXIS OF CISPLATIN-INDUCED EMESIS
Authors: NAVARI R GANDARA D HESKETH P HALL S MAILLIARD J RITTER H FRIEDMAN C FITTS D
Citation: R. Navari et al., COMPARATIVE CLINICAL-TRIAL OF GRANISETRON AND ONDANSETRON IN THE PROPHYLAXIS OF CISPLATIN-INDUCED EMESIS, Journal of clinical oncology, 13(5), 1995, pp. 1242-1248
PHARMACOKINETICS AND BIOEQUIVALENCE OF ETOPOSIDE FOLLOWING INTRAVENOUS ADMINISTRATION OF ETOPOSIDE PHOSPHATE AND ETOPOSIDE IN PATIENTS WITHSOLID TUMORS
Authors: KAUL S IGWEMEZIE LN STEWART DJ FIELDS SZ KOSTY M LEVITHAN N BUKOWSKI R GANDARA D GOSS G ODWYER P SCHACTER LP BARBHAIYA RH
Citation: S. Kaul et al., PHARMACOKINETICS AND BIOEQUIVALENCE OF ETOPOSIDE FOLLOWING INTRAVENOUS ADMINISTRATION OF ETOPOSIDE PHOSPHATE AND ETOPOSIDE IN PATIENTS WITHSOLID TUMORS, Journal of clinical oncology, 13(11), 1995, pp. 2835-2841
CONCOMITANT AND ALTERNATING RADIATION-THERAPY (RT) AND CHEMOTHERAPY (CT) FOR INOPERABLE, MO, NONSMALL CELL LUNG CANCERS (NSCLC) - A CONSENSUS REPORT
Authors: MIRIMANOFF RO RUBIN P COX JD GANDARA D GRUNENWALD D HAZUKA M JASSEM J KOMAKI R MATTSON K MCDONALD S MORNEX F PALAZZI M PAVY JJ REBOUL F SHAW E STORME G STOUT R SUTEDJA T TROVO MD VOKES E ZANELLI G
Citation: Ro. Mirimanoff et al., CONCOMITANT AND ALTERNATING RADIATION-THERAPY (RT) AND CHEMOTHERAPY (CT) FOR INOPERABLE, MO, NONSMALL CELL LUNG CANCERS (NSCLC) - A CONSENSUS REPORT, Lung cancer, 11, 1994, pp. 5-8
PREDICTORS OF SURVIVAL FOLLOWING RELAPSE OR PROGRESSION OF SMALL-CELLLUNG-CANCER - SOUTHWEST-ONCOLOGY-GROUP STUDY 8605 REPORT AND ANALYSISOF RECURRENT DISEASE DATA-BASE
Authors: ALBAIN KS CROWLEY JJ HUTCHINS L GANDARA D OBRYAN RM VONHOFF DD GRIFFIN B LIVINGSTON RB
Citation: Ks. Albain et al., PREDICTORS OF SURVIVAL FOLLOWING RELAPSE OR PROGRESSION OF SMALL-CELLLUNG-CANCER - SOUTHWEST-ONCOLOGY-GROUP STUDY 8605 REPORT AND ANALYSISOF RECURRENT DISEASE DATA-BASE, Cancer, 72(4), 1993, pp. 1184-1191
Risultati: 1-7 |